|
|
| (84 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) |
| Zeile 1: |
Zeile 1: |
| | __NOTOC__ | | __NOTOC__ |
| | *'''[[Further reading]]''' | | *'''[[Further reading]]''' |
| − | {{tp|p=32362782|t=2020. Aktuelle Informationen zu COVID-19 auf einer Plattform ? zeitschriftenübergreifend |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Unproven ideas]]''' | | *'''[[Unproven ideas]]''' |
| | + | |
| | *'''[[Reviews on covid19 disease]]''' | | *'''[[Reviews on covid19 disease]]''' |
| − | {{tp|p=32330209|t=ä. A precision medicine approach to managing 2019 novel coronavirus pneumonia |pdf=|usr=}}
| + | *'''[[Clinical guidelines and advice]]''' |
| − | {{tp|p=32278960|t=2020. COVID-19 from veterinary medicine and one health perspectives: What animal coronaviruses have taught us |pdf=|usr=}}
| + | |
| − | {{tp|p=32345483|t=ä. CCOVID-19 with Pulmonary Involvement. An Autoimmune Disease of Known Cause |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| − | *'''[[Clinical guidelines and advice]]'''
| |
| | | | |
| | *'''[[Respiration mgmt]]''' | | *'''[[Respiration mgmt]]''' |
| − | ----
| |
| | | | |
| | + | *'''[[Diagnosis (Laboratory)]]''' |
| | | | |
| − | *'''[[Structure of covid19]]'''
| |
| − | {{tp|p=32269081|t=2020. Phylogenetic network analysis of SARS-CoV-2 genomes |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Diagnosis (Lung CT, Sonography)]]''' |
| | | | |
| − | *'''[[Target binding and uptake]]''' | + | *'''[[Diagnosis (other modalities)]]''' |
| − | {{tp|p=32165541|t=2020. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells |pdf=|usr=}}
| + | |
| − | {{tp|p=32364961|t=2020. Severe respiratory SARS-CoV2 infection: Does ACE2 receptor matter?|pdf=|usr=}}
| + | |
| | | | |
| | | | |
| − | *'''[[Cytopathic effects]]'''
| |
| | | | |
| | + | |
| | + | *'''[[Structure of covid19]]''' |
| | + | |
| | + | |
| | + | *'''[[Target binding and uptake]]''' |
| | + | *'''[[Cytopathic effects]]''' |
| | *'''[[Secretion and shedding]]''' | | *'''[[Secretion and shedding]]''' |
| − | {{tp|p=32304647|t=2020. SARS-CoV-2 shedding and infectivity |pdf=|usr=}}
| |
| − | {{tp|p=32304646|t=ä. SARS-CoV-2 shedding and infectivity ? Authors reply |pdf=|usr=}}
| |
| | | | |
| | | | |
| Zeile 40: |
Zeile 37: |
| | *'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]''' | | *'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]''' |
| | | | |
| − | ----
| |
| | | | |
| | | | |
| | + | *'''[[Pathobiology]]''' |
| | | | |
| | | | |
| − | *'''[[Early symptoms]]''' | + | *'''[[Disease Models]]''' |
| | | | |
| − | *'''[[Systemic disease, any manifestations]]'''
| |
| | | | |
| − | *'''[[Co-Infection]]''' | + | *'''[[Similar diseases and pathomechanisms]]''' |
| − | {{tp|p=32192233|t=2020. Co-infection with SARS-CoV-2 and Human Metapneumovirus |pdf=|usr=}}
| + | |
| | | | |
| − | *'''[[ARDS]]'''
| |
| | | | |
| − | *'''[[Pulmonary embolism, coagulation]]'''
| |
| − | {{tp|p=32356640|t=2020. SARS-CoV-2 pneumonia and pulmonary embolism in a 66-year-old female |pdf=|usr=}}
| |
| − | {{tp|p=32329980|t=2020. SARS-CoV-2 infection masquerading as a possible pulmonary embolism |pdf=|usr=}}
| |
| − | {{tp|p=32351657|t=ä. Arterial and venous abdominal thrombosis in a 79-year-old woman with COVID-19 pneumonia |pdf=|usr=}}
| |
| | | | |
| | | | |
| | + | *'''[[Early symptoms]]''' |
| | | | |
| − | *'''[[Hematology]]''' | + | *'''[[Systemic disease, any manifestations]]''' |
| − | {{tp|p=32294340|t=ä. Immune Thrombocytopenic Purpura in a Patient with Covid-19 |pdf=|usr=}}
| + | |
| | | | |
| | + | *'''[[Co-Infection]]''' |
| | | | |
| − | *'''[[Microvascular]]'''
| |
| | | | |
| − | *'''[[Heart]]''' | + | *'''[[Pulmonary embolism, coagulation]]''' |
| − | *'''[[Neurology, ophthalmology, orl]]'''
| + | |
| | | | |
| − | *'''[[Dermatology]]'''
| |
| | | | |
| | | | |
| − | *'''[[Gastroenterology, hepatology]]'''
| |
| − | {{tp|p=32328338|t=2020. Anal swab findings in an infant with COVID?19 |pdf=|usr=}}
| |
| − | {{tp|p=32356641|t=2020. Addressing multiple gastroenterological aspects of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32250094|t=2020. Gastrointestinal symptoms as the first, atypical indication of severe acute respiratory syndrome coronavirus 2 infection |pdf=|usr=}}
| |
| | | | |
| | | | |
| − | *'''[[Kidney, urology]]''' | + | *'''[[Hematology]]''' |
| − | {{tp|p=32362571|t=2020. SARS-CoV-2 and the testis: similarity with other viruses and routes of infection |pdf=|usr=}}
| + | |
| − | ----
| + | |
| | | | |
| | | | |
| − | *'''[[Pathobiology]]'''
| |
| − | {{tp|p=32326988|t=ä. Lactose Dehydrogenase in Patients with Severe COVID-19: A Meta-Analysis of Retrospective Study |pdf=|usr=}}
| |
| − | {{tp|p=32339247|t=ä. Does apolipoprotein E genotype predict COVID-19 severity?|pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Heart]]''' |
| | | | |
| | | | |
| − | *'''[[Disease Models]]'''
| |
| − | {{tp|p=32303993|t=ä. Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Neurology, ophthalmology, orl]]''' |
| | | | |
| − | *'''[[Similar diseases and pathomechanisms]]'''
| |
| − | {{tp|p=32342879|t=ä. COVID-19 and radiation induced pneumonitis: overlapping clinical features of different diseases |pdf=|usr=}}
| |
| | | | |
| | | | |
| − | ----
| + | *'''[[Dermatology]]''' |
| | | | |
| | | | |
| − | *'''[[Diagnosis (Laboratory)]]'''
| |
| − | {{tp|p=C7187661|t=ä. Group Testing for SARS-CoV-2: Forward to the Past?|pdf=|usr=}}
| |
| − | {{tp|p=32329979|t=2020. COVID-19 rapid antibody cassette point of care tests: practical considerations |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Gastroenterology, hepatology]]''' |
| | | | |
| | + | *'''[[Kidney, urology]]''' |
| | | | |
| − | *'''[[Diagnosis (Lung CT, Sonography)]]''' | + | *'''[[The morbid survivor]]''' |
| | | | |
| | + | *'''[[Risk and special populations]]''' |
| | | | |
| − | *'''[[Diagnosis (other modalities)]]'''
| |
| | | | |
| | | | |
| | + | *'''[[Case reports]]''' |
| | | | |
| − | *'''[[Risk and special populations]]'''
| |
| | | | |
| | | | |
| | | | |
| | | | |
| − | *'''[[The morbid survivor]]'''
| |
| − | *'''[[Case reports]]'''
| |
| | | | |
| | | | |
| Zeile 128: |
Zeile 102: |
| | *'''[[Registries]]''' | | *'''[[Registries]]''' |
| | | | |
| − | ----
| |
| | | | |
| | + | *'''[[Trials]]''' |
| | | | |
| − | *'''[[Trials]]'''
| |
| | *'''[[Candidate Compounds Covid19]]''' | | *'''[[Candidate Compounds Covid19]]''' |
| | | | |
| | | | |
| | + | *'''[[Other routes of infection]]''' |
| | | | |
| − | ----
| |
| − |
| |
| − | *'''[[Remission, recurrence and persistence]]'''
| |
| − | {{tp|p=32308203|t=2020. Patients with respiratory symptoms are at greater risk of COVID-19 transmission |pdf=|usr=}}
| |
| − |
| |
| − | *'''[[Other routes of infection]]'''
| |
| − | {{tp|p=32291098|t=ä. Assessing Viral Shedding and Infectivity of Tears in Coronavirus Disease 2019 (COVID-19) Patients |pdf=|usr=}}
| |
| | | | |
| | *'''[[Biophysics of aerosols]]''' | | *'''[[Biophysics of aerosols]]''' |
| | | | |
| − | *'''[[Passive protective equipment]]'''
| |
| | | | |
| | | | |
| − | *'''[[Running your hospital]]'''
| |
| | | | |
| − | *'''[[Mental aspects of health professionals]]''' | + | *'''[[Passive protective equipment]]''' |
| | | | |
| | | | |
| | | | |
| | + | *'''[[Running your hospital]]''' |
| | | | |
| | | | |
| | + | *'''[[Mental aspects of health professionals]]''' |
| | | | |
| | + | *'''[[Socio-psychiatric aspects of the status hygienicus]]''' |
| | | | |
| | | | |
| | | | |
| − |
| |
| − | *'''[[Socio-psychiatric aspects of the status hygienicus]]'''
| |
| | | | |
| | *'''[[Avoiding clinical medicine in other diseases]]''' | | *'''[[Avoiding clinical medicine in other diseases]]''' |
| − | {{tp|p=32283124|t=ä. Reduction in ST-Segment Elevation Cardiac Catheterization Laboratory Activations in the United States during COVID-19 Pandemic |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| Zeile 172: |
Zeile 138: |
| | | | |
| | *'''[[Economic aspects of the status hygienicus]]''' | | *'''[[Economic aspects of the status hygienicus]]''' |
| − | {{tp|p=32242087|t=ä. What the stock market tells us about the post-COVID-19 world |pdf=|usr=}}
| |
| − | {{tp|p=32313382|t=ä. Can Global Pharmaceutical Supply Chains Scale Up Sustainably for the COVID-19 Crisis?|pdf=|usr=}}
| |
| − | {{tp|p=32313383|t=2020. A brave new world: Lessons from the COVID-19 pandemic for transitioning to sustainable supply and production |pdf=|usr=}}
| |
| | | | |
| − | *'''[[Educational aspects of the status hygienicus]]'''
| |
| − | {{tp|p=32313309|t=ä. Education and the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32302818|t=2020. Impact Of Sars-Cov-2 And Its Reverberation In Global Higher Education And Mental Health |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Educational aspects of the status hygienicus]]''' |
| | ---- | | ---- |
| | | | |
| | | | |
| | *'''[[Host, vector, one health, atmospheric aspects]]''' | | *'''[[Host, vector, one health, atmospheric aspects]]''' |
| − | {{tp|p=32300261|t=2020. Severe air pollution events not avoided by reduced anthropogenic activities during COVID-19 outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32333993|t=ä. Does the pathogenesis of SAR-CoV-2 virus decrease at high-altitude?|pdf=|usr=}}
| |
| − |
| |
| − |
| |
| | | | |
| | *'''[[Origin of Covid19]]''' | | *'''[[Origin of Covid19]]''' |
| Zeile 194: |
Zeile 151: |
| | | | |
| | | | |
| − | *'''[[Failure of executive measures]]'''
| |
| | | | |
| | | | |
| | | | |
| | + | *'''[[Remission, recurrence and persistence]]''' |
| | + | |
| | + | |
| | + | |
| | + | *'''[[Failure of executive measures]]''' |
| | ---- | | ---- |
| | *'''[[Failure of politics and public health guidance]]''' | | *'''[[Failure of politics and public health guidance]]''' |
| − |
| |
| | | | |
| | | | |
| | *'''[[Political abuse of Covid19]]''' | | *'''[[Political abuse of Covid19]]''' |
| − | {{tp|p=32203324|t=ä. COVID-19 and the crisis of national development |pdf=|usr=}}
| |
| | | | |
| | | | |
| Zeile 211: |
Zeile 170: |
| | | | |
| | *'''[[Lost civilization]]''' | | *'''[[Lost civilization]]''' |
| | + | |
| | ---- | | ---- |
| | | | |
| | | | |
| | *'''[[History of covid19 exploration]]''' | | *'''[[History of covid19 exploration]]''' |
| − | {{tp|p=32088858|t=ä. Puzzle of highly pathogenic human coronaviruses (2019-nCoV) |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| | *'''[[misc.]]''' | | *'''[[misc.]]''' |
| | + | |
| | | | |
| | *'''[[Research tools]]''' | | *'''[[Research tools]]''' |
| Zeile 224: |
Zeile 182: |
| | | | |
| | | | |
| − | *'''[[PrePrint scene''']] | + | |
| − | *[https://prelights.biologists.com/ prelights]
| + | {{tp|p=27490990|t=2017. AVCpred: an integrated web server for prediction and design of antiviral compounds |pdf=|usr=}} |
| | + | {{tp|p=25040500|t=2014. Engineering large viral DNA genomes using the CRISPR?Cas9 system |pdf=|usr=}} |
| | + | |
| | + | |
| | + | *'''[[PrePrint scene]]''' |
| | + | |
| | | | |
| | *'''[[from the ads]]''' | | *'''[[from the ads]]''' |
| − | *[lifechemicals.com antiviral candidate drugs]
| + | |
| − | *[biomol.com assays cytokines general spectrum]
| + | |
| − | *[labospace.com custom single probe assay 400 possible cytokines and so on]
| + | |
| − | *[codexdna.com dna synthesis]
| + | |
| − | *[eclipsebio.com around rna]
| + | |
| − | *[btbemulsions.com freud adjuvant kit]
| + | |
| − | *[biophysics.com div.]
| + | |
| − | *[molecular-machines.com microdissection]
| + | |
| | *'''[[Current state of coviki.org]]''' | | *'''[[Current state of coviki.org]]''' |
| | + | *'''[[on-topic personal thoughts]]''' |
